ASCO GU 2021 Bladder Cancer - Results from #40

Viewing 41-50 of 50 articles

ASCO GU 2021: Best of Journals: Urothelial Cancer - Medical Oncology

ASCO GU 2021: Germline Alterations in Cancer Susceptibility Genes in Women with High-Risk Bladder Cancer: Implications for Germline Testing and Clinical Management

ASCO GU 2021: Impact of Subsequent Therapy on Survival in KEYNOTE-361: Pembrolizumab (Pembro) plus Chemotherapy (Chemo) or Pembro Alone Versus Chemo as First-Line Therapy for Advanced Urothelial Carcinoma

ASCO GU 2021: Post-Hoc Analysis of Long-Term Outcomes In Patients with CR, PR, or SD to Pembrolizumab Platinum-Based Chemotherapy as 1L Therapy for Advanced Urothelial Carcinoma in KEYNOTE-361

ASCO GU 2021: Efficacy of Enfortumab Vedotin in Advanced Urothelial Cancer: Retrospective Analysis of the Urothelial Cancer Network To Investigate Therapeutic Experiences (UNITE) Study

ASCO GU 2021: TROPiCS-04: Study of Sacituzumab Govitecan in Metastatic Or Locally Advanced Unresectable Urothelial Cancer That Has Progressed After Platinum and Checkpoint Inhibitor Therapy

ASCO GU 2021: CDKN2A Alterations as Markers of Immune Checkpoint Blockade Resistance In Urothelial Carcinoma

ASCO GU 2021: Treatment Patterns Among Patients with Advanced Urothelial Carcinoma Following Discontinuation of PD1/L1 Inhibitor Therapy

ASCO GU 2021: Avelumab First-Line Maintenance plus Best Supportive Care (BSC) Versus BSC Alone for Advanced Urothelial Carcinoma: JAVELIN Bladder 100 Japanese Subgroup Analysis

ASCO GU 2021: Genomic Characterization of Bladder Cancer with Variant Histology

1
2
3